IJPR  articles are Indexed in SCOPUSClick Here     Impact Factor for Five Years is 0.13 (2013 - 2018).    

logo

INTERNATIONAL JOURNAL OF PHARMACEUTICAL RESEARCH

A Step Towards Excellence

IJPR included in UGC-Approved List of Journals - Ref. No. is SL. No. 4812 & J. No. 63703

Published by : Advanced Scientific Research
ISSN
0975-2366
Current Issue
No Data found.
Article In Press
Life review of elderly depression
Development and application of ATR-FTIR spectroscopy for mixture homogeneity in pharmaceutical application
The Increasing Damage in Tubular Cell of Infant Mice’s Kidneys from Carbofuran Exposure during its Mothers’ Lactation Period
Trend of transsexualism problem and its implications towards muslim community in Malaysia
Development and validation of RP-HPLC method for the estimation of pidotimod in tablet dosage form
Evaluation of neurotoxicity of the ethanolic bark extract of Holarrhena pubescens Wall. ex G.Don in mice
Design, synthesis and evaluation of 2-aminobenzimidazole derivatives: strong candidate for PPAR gamma agonists.
Prediction of Heart Disease Using Feature Selection and Random Forest Ensemble Method
Strategies for Antiviral Drugs from Plants by Targeting the Hemagglutinin, Neuraminidase and other receptors of Influenza A virus
The impact of human resource and quality management in health care: A Review
12345678910...
ADOBE READER

(Require Adobe Acrobat Reader to open, If you don't have Adobe Acrobat Reader)

Index Page 1
Click here to Download
IJPR 9[3] July - September 2017 Special Issue

July - September 9[3] 2017

Click to download
 

Article Detail

Label
Label
Results of molecular genetic studies of progressing muscular dystrophies of dushen/Becker in Uzbekistan

Author: UMIDA OMONOVA, YAKUTKHON MADJIDOVA, UMIDA BABADJANOVA, NODIRA KHAMIDOVA, KAMILJON BOBONIYAZOV
Abstract: Direct DNA diagnostics was performed for 91 patients with DMD/B from 81 families, 84 (92.3%) patients with Duchenne muscular dystrophy, 7 (8.6%) patients with Becker muscular dystrophy. The analysis was carried out on 20 exons of the dystrophin gene — the promoter region, 3, 4, 6, 8, 13, 17, 19, 32, 42, 43, 44, 45, 47, 48, 50, 51, 52, 53, 60 exons. Indirect diagnosis was carried out in 21 families burdened with DMD/B using intragenic highly polymorphic markers located in the 45th (STR-45), 49th (STR-49), 50th (STR-50) gene introns. According to the results of molecular diagnostics, 33 deletions were not detected in 33 patients (36.3%) of 32 families (39.5%), and major gene deletions were detected in 58 patients (63.7%) of 49 families (60.5%) dystrophin of various lengths - from one to nine exons: in 65.3% of families, extended deletions were verified, deletions of one exon were found in 34.7% of families. The main deletion spectrum was located in the distal part of the dystrophin gene - the 3’-end (deletions of 40-60 exons), which amounted to 81.6% (40 families, 47 patients).
Keyword: Duchenne/Becker progressive muscular dystrophy, dystrophin gene, PCR diagnostics, indirect DNA diagnostics, prenatal diagnostics.
DOI: https://doi.org/10.31838/ijpr/2020.12.03.242
Download: Request For Article
 












ONLINE SUBMISSION
USER LOGIN


Username
Password
Login | Register
News & Events
SCImago Journal & Country Rank

Terms and Conditions
Disclaimer
Refund Policy
Instrucations for Subscribers
Privacy Policy

Copyrights Form

0.12
2018CiteScore
 
8th percentile
Powered by  Scopus
Google Scholar

hit counters free